JLE

Bulletin du Cancer

MENU

Treatment of peritoneal carcinomatosis with surgery and hyperthermic peroperative intraperitoneal chemotherapy (HIPEC): new aspects and validated indications Volume 95, issue 1, janvier 2008

Authors
Département médicochirurgical de pathologie digestive, Hôpital Lariboisière, 2, rue Ambroise-Paré, 75010 Paris, Département d’anesthésie–réanimation, Hôpital Lariboisière, 2, rue Ambroise-Paré, 75010 Paris, Pharmacie, Hôpital Lariboisière, 2, rue Ambroise-Paré, 75010 Paris, Service d’hépato-gastroentérologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris

Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) is now an entire part of treatment of peritoneal dissemination of colorectal malignancy, and it’s possible to hope prolonged survival. This treatment is more and more codified. Four indications are recognized by some tree national evaluation committees : the French ANAES, the British NICE and the Canadian CEPO : colorectal carcinoma, carcinoma of the appendix, pseudomyxoma peritonei and mesothelioma. Last big published series results show a decrease of morbidity and mortality and interest of using new drugs like oxaliplatine. Indications have to be more homogeneous and based on evidences.